Boehringer Ingelheim International Gmbh

Yale University

Qx Therapeutics Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Hb Therapeutics Inc.

Moexa Pharmaceuticals Limited

Boehringer Ingelheim Pharma Gmbh & Co Kg

Ho Yin Lo

Stephane De Lombaert

Peter Allen Nemoto

Weimin Liu

Zhidong Chen

Pui Leng Loke

Doris Riether

Renee M Zindell

Todd Bosanac

Lifen Wu

Alessandra Bartolozzi

Heather Tye

Alan Olague

John David Huber

Hidenori Takahashi

Tina Marie Morwick

Xin Guo

Jonathon Alan Dines

Michel Jose Emmanuel

Brian Nicholas Cook

Jin Mi Kim

Dianqing Wu

Kevin Chungeng Qian

Chuk Chui Man

Ming-Hong Hao

Lei Qiao

Roger John Snow

Charles Lawrence Cywin

Michael Peter Winters

Asitha Abeywardane

Ji Wang

Stéphane De Lombaert

Joerg Bentzien

Gregory Paul Roth

Steven John Taylor

Roman Wolfgang Fleck

Steven S Pullen

Kevin J Moriarty

Chunhai Hao

Anita Bellail

Tina Morwick

Smad3 inhibitor compounds, specifically a compound of Formula 1 or Formula 2, or a pharmaceutically acceptable salt thereof, and its use in treating or preventing cell proliferation or cancer in a subject are provided.

SMAD3 inhibitors

The present invention relates to the field of anti-cancer compounds. More particularly, the invention relates to a family of benzothiazolyl urea or thiorurea compound useful as such agents. The present invention also relates to methods for treating cancers using these compounds.

Compositions and methods for treating cancer

The present invention provides methods and compositions for treating and preventing lung injuries due to or associated with coronavirus infections that cause Severe Acute Respiratory Syndrome, including COVID-19. More specifically the present invention provides methods for treating or preventing the lung injuries associated with SARS-CoV-2 infections, such as acute lung injury (ALI), lung fibrosis, and acute respiratory distress syndrome (ARDS). The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising a protein kinase inhibitor compound having MAP3K2/MAP3K3 inhibition activity, such as pazopanib or nintedanib, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, to a patient in need thereof. The present invention also provides devices for administering the compositions.

Compositions and methods for treating lung injuries associated with SARS-CoV-2 infections

Compositions and methods for treating lung injuries associated with SARS-COV-2 infections

The present invention relates to compound of formula (I): or pharmaceutically acceptable salts thereof, wherein R-R, A and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Heterocyclic compounds as inhibitors of leukotriene production

Disclosed are small molecule inhibitors which are useful in treating various diseases and conditions involving chymase.

Benzimidazolone chymase inhibitors

Disclosed are small molecule inhibitors of the formula (I): and the pharmaceutical compositions thereof and processes of making the same. The compounds are useful in treating various diseases and conditions involving chymase. 

Aza-benzimidazolone Chymase inhibitors

The present invention relates to compounds of formula (IA) and (IB): and pharmaceutically acceptable salts thereof, wherein R-Rare as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Benzimidazole inhibitors of leukotriene production

The present invention relates to compounds of formula (IA), (IB) and (IC): and pharmaceutically acceptable salts thereof, wherein R-Rare as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

The present invention relates to compound of formula (I): or pharmaceutically acceptable salts thereof, wherein R-Rare as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Oxadiazole inhibitors of leukotriene production

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salt thereof, wherein Xto X, Rto R, A, B, D and m are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Indolizine inhibitors of leukotriene production

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R-Rare as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Disclosed are small molecule inhibitors which are useful in treating various diseases and conditions involving Chymase.

Quinazolinedione chymase inhibitors

Disclosed are substituted benzimidazole compounds of formula (I): wherein R, R, R, Rand Xare defined herein. The compounds of the invention inhibit Itk kinase and are therefore useful for treating diseases and pathological conditions involving inflammation, immunological disorders and allergic disorders. Also disclosed are processes for preparing these compounds and to pharmaceutical compositions comprising these compounds.

Substituted benzimidazole compounds

Growing community of inventors

Bethel, CT, United States of America

Ho Yin Lo